Background: Melioidosis pneumonia, caused by the bacterium , is a serious infectious disease prevalent in tropical regions. Chest computed tomography (CT) has emerged as a valuable tool for assessing the severity and progression of lung involvement in melioidosis pneumonia. However, there persists a need for the quantitative assessment of CT characteristics and staging methodologies to precisely anticipate disease progression. This study aimed to quantitatively extract CT features and evaluate a CT score-based staging system in predicting the progression of melioidosis pneumonia.
Methods: This study included 97 patients with culture-confirmed melioidosis pneumonia who presented between January 2002 and December 2021. Lung segmentation and annotation of lesions (consolidation, nodules, and cavity) were used for feature extraction. The features, including the involved area, amount, and intensity, were extracted. The CT scores of the lesion features were defined by the feature importance weight and qualitative stage of melioidosis pneumonia. Gaussian process regression (GPR) was used to predict patients with severe or critical melioidosis pneumonia according to CT scores.
Results: The melioidosis pneumonia stages included acute stage (0-7 days), subacute stage (8-28 days), and chronic stage (>28 days). In the acute stage, the CT scores of all patients ranged from 2.5 to 6.5. In the subacute stage, the CT scores for the severe and mild patients were 3.0-7.0 and 2.0-5.0, respectively. In the chronic stage, the CT score of the mild patients fluctuated approximately between 2.5 and 3.5 in a linear distribution. Consolidation was the most common type of lung lesion in those with melioidosis pneumonia. Between stages I and II, the percentage of severe scans with nodules dropped from 72.22% to 47.62% (P<0.05), and the percentage of severe scans with cavities significantly increased from 16.67% to 57.14% (P<0.05). The GPR optimization function yielded area under the receiver operating characteristic curves of 0.71 for stage I, 0.92 for stage II, and 0.87 for all stages.
Conclusions: In patients with melioidosis pneumonia, it is reasonable to divide the period (the whole progression of melioidosis pneumonia) into three stages to determine the prognosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11151251 | PMC |
http://dx.doi.org/10.21037/qims-23-1476 | DOI Listing |
South Afr J Crit Care
July 2024
Department of Critical Care Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Background: Melioidosis cases are increasing in Southeast Asia, posing a significant challenge owing to the rising number of diabetic and immune compromised patients. Pneumonia is the most common presentation of melioidosis, while cutaneous melioidosis is rare.
Objectives: We report a case of primary cutaneous melioidosis (PCM) that eventually required intensive care unit (ICU) management.
Quant Imaging Med Surg
December 2024
Department of Microbiology, AII India Institute of Medical Sciences, Bhubaneswar, India.
Infect Med (Beijing)
December 2024
Department of Clinical Microbiology and Immunology, College of Pharmacy and Medical Laboratory, Army Medical University (Third Military Medical University), Chongqing 400038, China.
Background: is a gram-negative bacterium widely found in Southeast Asia and northern Australia. This bacterium, which lacks an available vaccine, is the causative agent of melioidosis and has properties that potentially enable its exploitation as a bioweapon.
Methods: Polymerase chain reaction assays targeting each of the lipopolysaccharide (LPS) genetic types were used to investigate genotype frequencies in populations.
Antimicrob Agents Chemother
December 2024
Department of Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA.
LPC-233 (a.k.a.
View Article and Find Full Text PDFFront Immunol
December 2024
Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, United States.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!